We wanted to let you know that Sarepta Therapeutics will host a webcast and conference call on October 17. Please see information below from Sarepta. We encourage you to submit […]
GSK and Prosensa will hold a joint webinar on 15th October at 16:00 – 17:30 GMT (17:00 – 18:30 CET, 12:00 – 13:30 EST, 09:00 – 10:30 PST). Following […]
WMS 2013 was full of excitement and interest as results of current clinical trials and early stage research were discussed. Here are some highlights, thank you Abby Bronson for summarizing […]
Dr. Adeline Vulin from Nationwide Children’s Hospital presented the latest data from her work in Dr. Kevin Flanigan’s lab on the new duplication mouse model and the results of exon […]
Here are top line notes from the PRO044 presentation at World Muscle Society, Oct 4. Age of inclusion: 5-16 Mean age: 9 The drug was well tolerated. They saw trace […]
Conference call and live webcast scheduled for 11:00 a.m. ET (5:00 p.m. CET) Tuesday, October 8, 2013 LEIDEN, The Netherlands – October 3, 2013 – Prosensa Holding N.V. (NASDAQ: RNA), […]
We wanted to let Duchenne families know about a new online resource on exon skipping from Sarepta Therapeutics. Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today […]
We are encouraged by the promising Phase IIb data for eteplirsen, an exon-skipping compound, which we hope could be a breakthrough treatment for Duchenne muscular dystrophy. Currently, there is no […]
GlaxoSmithKline (GSK) and Prosensa today announced that GSK’s Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable […]
